Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer
September 20 2022 - 7:30AM
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”),
a biotechnology company transforming drug discovery with its
proprietary computational discovery platform identifying novel
allosteric binding sites and creating small molecule treatments,
today announced that Matthias Alder, the Company’s current Chief
Operating Officer, has been appointed as the Company’s Chief
Executive Officer, effective immediately. He succeeds Eric Richman,
who has served in the role since July 2020 and led the Company
through its initial public offering in March 2021. Mr. Alder was
also appointed to the Company’s Board of Directors effective as of
today and, with his appointment, the size of the Board was
increased to eight members. Mr. Richman will continue to serve as a
member of the Board and as a senior advisor to the Company.
“On behalf of the Board of Directors, I would
like to thank Eric for his invaluable contributions leading the
transformation of Gain Therapeutics from a private company to a
publicly traded company, and for establishing an impressive
scientific advisory board and leading a strong management team. We
are pleased that Eric will continue to assist Gain Therapeutics as
a senior advisor and to continue to lead as a member of the board
with his extensive strategic and corporate leadership experience,”
said Khalid Islam, Ph.D., Chairman of Gain’s Board of Directors. “I
am delighted to welcome Matthias as CEO and as a member of our
Board of Directors. During the course of the last year, Matthias
has worked closely with Eric in shaping and leading the Company’s
corporate development strategy. As we enter the next phase of
growth for Gain, his proven ability to foster strong relationships
with collaboration partners in the pharmaceutical industry will be
instrumental in positioning Gain’s platform for expansion.”
“I am excited to be transitioning into the role
of CEO and leading Gain in our next phase of growth,” said Matthias
Alder. “Eric and I have forged a strong working relationship since
I joined Gain last year and I look forward to continuing to work
with him in his new consultant role. Gain is poised for success as
we focus on our continued execution against established strategic
objectives, including advancing our two lead programs in
Parkinson’s and Gaucher disease and expanding the application of
our proprietary computational drug discovery platform through
collaborations and strategic partnerships.”
Since joining Gain as Chief Operating Officer in
2021, Mr. Alder has been instrumental in building the Company’s
corporate and business development strategy and shaping the
Company’s operations. Mr. Alder brings more than 25 years of
experience in the pharmaceutical and biotechnology industries,
having held senior leadership roles in both U.S. and European-based
publicly traded companies leading business development,
strategy and a range of corporate functions. Prior to joining Gain,
he served as Chief Business Officer and Head of US Operations of
Autolus Therapeutics (Nasdaq: AUTL). Previously, Mr. Alder
held senior roles in business development, licensing, and legal
affairs at Sucampo Pharmaceuticals (Nasdaq: SCMP), Cytos
Biotechnology AG, and Micromet, Inc. Mr. Alder was formerly a
partner at Cooley LLP and previously served as Division Counsel at
Ciba-Geigy and Novartis. He earned his law degrees from the
University of Miami (LL.M.) and the University of Basel
(lic.iur).
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is transforming the drug discovery paradigm
with structurally targeted allosteric regulators identified with
its proprietary computational discovery platform SEE-Tx®. The
ability to identify never-seen-before allosteric targets on
proteins involved in diseases across the full spectrum of
therapeutic areas provides opportunities for a range of
drug-protein interactions, including protein stabilization, protein
destabilization, targeted protein degradation, allosteric
inhibition and allosteric activation. Gain’s pipeline spans
neurodegenerative diseases, lysosomal storage disorders, metabolic
diseases and oncology. Gain’s lead program in Parkinson’s disease
has been awarded funding support from The Michael J. Fox Foundation
for Parkinson’s Research (MJFF) and The Silverstein Foundation for
Parkinson’s with GBA, as well as from the Eurostars-2 joint program
with co-funding from the European Union Horizon 2020 research and
Innosuisse. For more information, please
visit https://www.gaintherapeutics.com.
Forward Looking Statements
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Words such as
“may,” “can,” “will,” “believe,” “expect,” “plan,” “anticipate,”
and similar expressions (as well as other words or expressions
referencing future events or circumstances) are intended to
identify forward-looking statements. All statements, other than
statements of historical facts, included in this press release are
forward-looking statements. These statements include, but are not
limited to, statements regarding the growth and strategic plans of
the Company including development of its current and future
collaborations and strategic partnerships. Such forward-looking
statements are based on current expectations about our future
goals, plans and objectives and involve inherent risks, assumptions
and uncertainties, including internal or external factors that
could delay, divert or change any of them in the next several
years, that are difficult to predict, may be beyond our control and
could cause our future financial results, goals, plans and
objectives to differ materially from those expressed in, or implied
by, the statements. No forward-looking statement can be guaranteed.
Forward-looking statements in this press release should be
evaluated together with the many risks and uncertainties that
affect the Company’s business, particularly those identified in the
risk factors discussion in the Company’s Annual Report on Form
10-K, as updated by subsequent Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K and other filings with the Securities
and Exchange Commission. All information in this press release is
as of the date of the release, and the Company undertakes no duty
to update this information, except as required by law.
Investor & Media
Contact:
Stacey JurchisonVP, Investor Relations(410)
474-8200sjurchison@gaintherapeutics.com
Noor PahlaviArgot Partners(212)
600-1902Gain@argotpartners.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Apr 2023 to Apr 2024